Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Infuscience
mi
from
Annandale, VA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Infuscience
mi
from
Annandale, VA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Illinois CancerCare-Peoria
mi
from
Peoria, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Illinois CancerCare-Peoria
mi
from
Peoria, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
David Fivenson, M.D. Dermatology, PLLC
mi
from
Ann Arbor, MI
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
David Fivenson, M.D. Dermatology, PLLC
mi
from
Ann Arbor, MI
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
.A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Gem-TABS in Unresectable Pancreatic Carcinoma
A Phase I Study of Oral Sodium Bicarbonate in Patients With Unresectable Pancreatic Carcinoma Treated With Gemcitabine
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Gem-TABS in Unresectable Pancreatic Carcinoma
A Phase I Study of Oral Sodium Bicarbonate in Patients With Unresectable Pancreatic Carcinoma Treated With Gemcitabine
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
New Haven, CT
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
New Haven, CT
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Roswell, GA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Roswell, GA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Indianapolis, IN
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Indianapolis, IN
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Baton Rouge, LA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Baton Rouge, LA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Las Vegas, NV
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Las Vegas, NV
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Charleston, SC
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Charleston, SC
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Richmond, VA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Richmond, VA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
A Phase II Study of Gemcitabine, Oxaliplatin and Bevacizumab Followed by 5-Fluorouracil, Oxaliplatin, Bevacizumab and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
A Phase II Study of Gemcitabine, Oxaliplatin and Bevacizumab Followed by 5-Fluorouracil, Oxaliplatin, Bevacizumab and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
St. Vincent's Medical Center
mi
from
Bridgeport, CT
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
St. Vincent's Medical Center
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
St. Francis Hospital Cancer Care Services
mi
from
Indianapolis, IN
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
St. Francis Hospital Cancer Care Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
mi
from
Baltimore, MD
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Surgical Oncology Associates
mi
from
Newport News, VA
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Surgical Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials